Protective effect of korean red ginseng extract on the infections by H1N1 and H3N2 influenza viruses in mice

Journal of Medicinal Food

Volumn 15, Issue 10, 2012, Pages 855-862

  Yoo, Dae Goon ^a,b   Kim, Min Chul ^a   Park, Min Kyung ^c,d   Song, Jae Min ^c,e   Quan, Fu Shi ^f   Park, Kyoung Mi ^a   Cho, Young Keol ^g   Kang, Sang Moo ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

^d Chungwoon University   (South Korea)

^e Sungshin Women's University   (South Korea)

^f Kyung Hee University Hospital   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

Author keywords

antioxidant activity; devil's claw extract; ginseng; immnunomodulation; mice

Indexed keywords

GAMMA INTERFERON; GINSENG EXTRACT; INTERLEUKIN 6;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; GROWTH INHIBITION; IN VITRO STUDY; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CROSS PROTECTION; HEMAGGLUTINATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PANAX; PANDEMICS; PLANT EXTRACTS; REPUBLIC OF KOREA;

EID: 84867302753     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2012.0017     Document Type: Article

References (45)

1. Thompson CI, Barclay WS, Zambon MC: Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. J Antimicrob Chemother 2004;53:759-765.
2. Moscona A: Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 2005;353:2633-2636.
3. Choi KT: Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C.A. Meyer. Acta Pharmacol Sin 2008;29:1109-1118.
4. Yuan CS, Wang CZ, Wicks SM, Qi LW: Chemical and pharmacological studies of saponins with a focus on American ginseng. J Ginseng Res 2010;34:160-167.
5. Sumiyoshi M, Sakanaka M, Kimura Y: Effects of Red Ginseng extract on allergic reactions to food in Balb/c mice. J Ethnopharmacol 2010;132:206-212.
6. Lee JH, Cho SH: Korean red ginseng extract ameliorates skin lesions in NC/Nga mice: an atopic dermatitis model. J Ethnopharmacol 2011;133:810-817.
7. Attele AS, Wu JA, Yuan CS: Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58: 1685-1693.
8. Park EK, Choo MK, Han MJ, Kim DH: Ginsenoside Rh1 possesses antiallergic and anti-inflammatory activities. Int Arch Allergy Immunol 2004;133:113-120.
9. Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 2004;9:259-274.
10. Panwar M, Samarth R, Kumar M, Yoon WJ, Kumar A: Inhibition of benzo(a)pyrene induced lung adenoma by Panax ginseng extract, EFLA400, in Swiss albino mice. Biol Pharm Bull 2005; 28:2063-2067.
11. Kim CS, Park JB, Kim KJ, et al.: Effect of Korea red ginseng on cerebral blood flow and superoxide production. Acta Pharmacol Sin 2002;23:1152-1156.
12. Lee B, Yang CH, Hahm DH, et al.: Inhibitory effects of ginseng total saponins on behavioral sensitization and dopamine release induced by cocaine. Biol Pharm Bull 2008;31:436-441.
13. Kim DY, Yang WM: Panax ginseng ameliorates airway inflammation in an ovalbumin-sensitized mouse allergic asthma model. J Ethnopharmacol 2011;136:230-235.
14. Wang J, Li S, Fan Y, et al.: Anti-fatigue activity of the watersoluble polysaccharides isolated from Panax ginseng C.A. Meyer. J Ethnopharmacol 2010;130:421-423.
15. Park JS, Park EM, Kim DH, et al.: Anti-inflammatory mechanism of ginseng saponins in activated microglia. J Neuroimmunol 2009;209:40-49.
16. Ernst E: Panax ginseng: an overview of the clinical evidence. J Ginseng Res 2010;34:259-263.
17. Cui Y, Shu XO, Gao YT, et al.: Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 2006;163:645-653.
18. Kim JH, Park CY, Lee SJ: Effects of sun ginseng on subjective quality of life in cancer patients: a double-blind, placebocontrolled pilot trial. J Clin Pharmacol Ther 2006;31:331-334.
19. Sung H, Jung YS, Cho YK: Beneficial effects of a combination of Korean red ginseng and highly active antiretroviral therapy in human immunodeficiency virus type 1-infected patients. Clin Vaccine Immunol 2009;16:1127-1131.
20. Sung H, Kang SM, Lee MS, Kim TG, Cho YK: Korean red ginseng slows depletion of CD4 T cells in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 2005;12:497-501.
21. Shin JY, Song JY, Yun YS, et al.: Immunostimulating effects of acidic polysaccharides extract of Panax ginseng on macrophage function. Immunopharmacol Immunotoxicol 2002;24:469-482.
22. Spelman K, Burns J, Nichols D, et al.: Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern Med Rev 2006;11:128-150.
23. Nakaya TA, Kita M, Kuriyama H, Iwakura Y, Imanishi J: Panax ginseng induces production of proinflammatory cytokines via toll-like receptor. J Interferon Cytokine Res 2004;24:93-100.
24. Rhule A, Navarro S, Smith JR, Shepherd DM: Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264.7 cells. J Ethnopharmacol 2006;106:121-128.
25. Ahn JY, Song JY, Yun YS, Jeong G, Choi IS: Protection of Staphylococcus aureus-infected septic mice by suppression of early acute inflammation and enhanced antimicrobial activity by ginsan. FEMS Immunol Med Microbiol 2006;46:187-197.
26. Ahn JY, Choi IS, Shim JY, et al.: The immunomodulator ginsan induces resistance to experimental sepsis by inhibiting Toll-like receptor-mediated inflammatory signals. Eur J Immunol 2006;36: 37-45.
27. Predy GN, Goel V, Lovlin R, et al.: Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosylsaccharides for preventing upper respiratory tract infections: a randomized controlled trial. CMAJ 2005;173:1043-1048.
28. McElhaney JE, Gravenstein S, Cole SK, et al.: A placebocontrolled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. J Am Geriatr Soc 2004;52:13-19.
29. Seida JK, Durec T, Kuhle S: North American (Panax quinquefolius) and Asian ginseng (Panax ginseng) preparations for prevention of the common cold in healthy adults: a systematic review. Evid Based Complement Alternat Med 2011;2011:282151.
30. Quan FS, Compans RW, Nguyen HH, Kang SM: Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008;82:1350-1359.
31. Quan FS, Huang C, Compans RW, Kang SM: Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007;81:3514-3524.
32. Quan FS, Compans RW, Cho YK, Kang SM: Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine 2007;25: 272-282.
33. Song JM, Kim YC, Barlow PG, et al.: Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 2010; 88:244-247.
34. Kikuchi Y, Sasa H, Kita T, et al.: Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs 1991;2: 63-67.
35. Quan FS, Steinhauer D, Huang C, et al.: A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008;26:3352-3361.
36. Hancock K, Veguilla V, Lu X, et al.: Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-1952.
37. Hossain MJ, Bourgeois M, Quan FS, et al.: Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol 2011;18: 2010-2017.
38. Quan FS, Vunnava A, Compans RW, Kang SM: Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One 2010;5:e9161.
39. Belshe RB: Current status of live attenuated influenza virus vaccine in the US. Virus Res 2004;103:177-185.
40. Belshe RB, Ambrose CS, Yi T: Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008;26(Suppl 4):D10-D16.
41. Yeung HW, Cheung K, Leung KN: Immunopharmacology of Chinese medicine 1, ginseng induced immunosuppression in virusinfected mice. Am J Chin Med 1982;10:44-54.
42. Kaneko H, Nakanishi K: Proof of the mysterious efficacy of ginseng: basic and clinical trials: clinical effects of medical ginseng, Korean red ginseng: specifically, its anti-stress action for prevention of disease. J Pharmacol Sci 2004;95:158-162.
43. Scaglione F, Cattaneo G, Alessandria M, Cogo R: Efficacy and safety of the standardised ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected]. Drugs Exp Clin Res 1996;22:65-72.
44. Zhai L, Li Y, Wang W, Hu S: Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens. Poult Sci 2011;90:1955-1959.
45. Kim DH, Moon YS, Lee TH, et al.: The inhibitory effect of ginseng saponins on the stress-induced plasma interleukin-6 level in mice. Neurosci Lett 2003;353:13-16.